Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMR Regimen for Ultra-high Risk CLL
NCT01670812Phase 3Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jan 2012
- Primary completion
- Jun 2013
- Modality
- Monoclonal Antibodies, Recombinant Proteins and Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab, methylprednisolone injection, fresh-frozen plasma in chronic lymphocytic leukemia (CLL), sponsored by Jiangsu Provincial People's Hospital. Status: unknown.
02
Drugs
rituximabmethylprednisolone injectionfresh-frozen plasma
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01670812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01670812.